Am J Transplant, Volume 17, Suppl 3 Archives - Page 76 of 181 - ATC Abstracts

2017 American Transplant Congress
DC-SIGN Functionalized Porous Silicon Nanoparticles Targeting to Human and Non-Human Primate Dendritic Cells.
S. Stead,¹ S. Kireta,² S. McInnes,³ P. Rose,¹ S. Jesudason,^1,2 S. Grey,⁴ D. Rojas-Canales,² R. Carroll,^1,2 N. Voelcker,⁴ P. Coates.^1,2
¹Medicine, University of Adelaide, Adelaide, Australia; ²Central and Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, Australia; ³ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide, Australia; ⁴Transplantation Immunology, Garven Institute of Medical Research, Sydney, Australia
Porous silicon (pSi) nanoparticles, modified to specifically target DC, provide a novel platform to carry and deliver immunosuppressive drugs. The aim was to conjugate DC-SIGN…
2017 American Transplant Congress
Renal Secretion of Organic Anionic Drugs Is Compromised in Renal Transplant Patients.
H. Kalluri,¹ P. Sood,² P. Randhawa,^2,3 S. Hariharan,² A. Tevar,² A. Humar,² R. Venkataramanan.^1,2,3
¹Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA; ²Thomas E. Starzl Transplantation Institute, University of Pittsburgh Medical Center, Pittsburgh, PA; ³Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA
Renal transplantation(Tx) is the treatment of choice for patients with ESRD. Transplanted kidneys undergo numerous insults including cold ischemia & warm reperfusion injury and are…
2017 American Transplant Congress
Clinical Outcomes in Older Kidney Transplant Recipients. A Single Center Experience.
L. Kamal, N. Hayde, P. Bedi, M. Lubetzky, M. Ajaimy, G. DeBoccardo, E. Akalin.
Montefiore Medical Center Transplant Center, Albert Einstein College of Medicine, NY
Background: We aimed to investigate the clinical outcomes of kidney transplant recipients 65 years and older.Methods: Between 1/2009 and 12/2014, 687 patients underwent a kidney…
2017 American Transplant Congress
Early and Late High Intrapatient Variability of Tacrolimus Levels Can Predict Late Renal Allograft Rejection.
D. Goodall, M. Willicombe, D. Swerdlow, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, United Kingdom
Introduction Nonadherence to immunosuppressive medication can start any time after transplantation and is associated with rejection and graft loss. We have previously shown that high…
2017 American Transplant Congress
Liver Transplantation Beyond MELD 40.
J. Scalea, D. Bruno, S. Hanish, J. Lamattina, J. Alvarez-Casas, S. Malik, A. Cimeno, S. Bartlett, R. Barth.
Surgery, University of Maryland, Baltimore, MD
OBJECTIVE(S): Liver allocation is prioritized for the sickest patients; however, poorer liver transplant (LTx) outcomes are associated with increasing MELD scores. While MELD is capped…
2017 American Transplant Congress
Greater Emphasis on Non-Eligible Donors as a Strategy to Decrease the Organ Shortage.
K. Croome, D. Lee, A. Keaveny, C. Taner.
Transplant, Mayo Clinic Florida, Jacksonville, FL
Background: OPO performance is generally evaluated by the number of organ procurement procedures divided by the number of eligible deaths(brain dead donors under age 70),…
2017 American Transplant Congress
Neurogenic Orthostatic Hypotension: An Iatrogenic Complication of Successful Pancreas Transplantation?
S. Kuten,¹ E. Simpson,¹ A. Gaber,¹ D. Nguyen,¹ E. Graviss,¹ S. Patel,² R. Knight.¹
¹Houston Methodist Hospital, Houston, TX; ²Veloxis Pharmaceuticals, Cary, NC
Abrupt improvement in glycemic control is known to cause treatment-induced neuoropathies in poorly-controlled diabetes (DM).1 Similarly, neurogenic orthostatic hypotension (OH) is a well-known complication of…
2017 American Transplant Congress
The Association of Donor Vasoactive Drugs with Pancreas Transplant Graft Survival.
I. Shapey,¹ P. Yianoullou,² A. Summers,² T. Augustine,² M. Rutter,¹ D. van Dellen.²
¹Division of Diabetes, Endocrinology and Gastroenterology, University of Manchester, Manchester, United Kingdom; ²Department of Renal and Pancreas Transplantation, Central Manchester University Hospitals, Manchester, United Kingdom
Introduction: Vasoactive drugs (VaD) are commonly used to correct abnormal haemodynamics of organ donors in Intensive Care Units (ICU). VaDs can differentially affect insulin secretion…
2017 American Transplant Congress
eHealth Literacy and Patient Portal Utilization Among Transplant Recipients.
K. Smith, A. Ruiz, J. Wedd, S. Pastan, R. Parker, R. Patzer.
Emory Transplant Center, Atlanta, GA
Background: Healthcare systems are required to engage patients with web-based patient portals. eHealth literacy is a distinct type of health literacy needed to properly understand…
2017 American Transplant Congress
Lymphoproliferative Disorders After Renal Transplantation Along Two Decades: A Large Longitudinal Study.
A. Franco,¹ D. Hernandez,² N. Maruri,³ A. Alonso,⁴ M. Crespo,⁵ A. Mazuecos,⁶ C. Diaz-Corte,⁷ M. Gentil.⁸
¹Nephrology, Hospital General, Alicante, Spain; ²Nephrology, Hospital Carlos Haya, Málaga, Spain; ³Nephrology, Hospital Cruces, Bilbao, Spain; ⁴Nephrology, Hospital Universitario, A Coruña, Spain; ⁵Nephrology, Hospital del Mar, Barcelona, Spain; ⁶Nephrology, Hospital Puerta del Mar, Cadiz, Spain; ⁷Nephrology, Hospital General, Oviedo, Spain; ⁸Nephrology, Hospital Virgen del Rocío, Sevilla, Spain
In a longuitudinal study,we evaluated the cumulative incidence of Posttransplant limphoproliferative disorders(PTLD),its relationship with Epstein Barr Virus (EBV),classical risk factors and outcome in 21546 single…